STUDresearch · Peptide
Prostamax
Also known as
KEDP · KEDP peptide · Lys-Glu-Asp-Pro · Lysyl-glutamyl-aspartyl-proline · H-Lys-Glu-Asp-Pro-OH · prostate bioregulator · Prostamax peptide · synthetic prostate tetrapeptide · Khavinson prostate peptide
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ / IM
Longevity & bioregulators
Systemic use is discussed for prostate goals; synthetic KEDP, animal-prostate extracts and herbal products are not interchangeable.
What people say
Prostamax is presented as synthetic KEDP, a four-amino-acid Khavinson-line peptide. The direct prostate evidence located here is a rat aseptic-injury model; human outcomes for synthetic KEDP should not inherit evidence from Prostatilen, Vitaprost, Libidon or herbal products sharing similar names.
Doses people talk about
Product identity and route were not independently verified. The reports are separate people, not a progression, and the 20 μg/kg IM formal amount belongs only to a surgically induced rat prostatitis model.
How it may feel
Accounts conflict sharply: a 750 mcg/day user reported steadier flow and fewer night trips with mouth-taping and hydration confounding; a 5 mg/day user reported improvement within days; 1 mg/day users reported no benefit, one person reported severe prostate pain, and another later called a rerun a bust.
Three-week report750 mcg each morning for three weeks
The user reported steadier flow and nocturia falling from four trips to one, but also began mouth taping and reduced overnight drinking. This account does not establish the outcome of another course.
Two-month non-response1 mg daily for two months
A user with self-reported BPH described zero benefit from injectable Prostamax and then no benefit from a separate Libidon course.
Higher-dose positive report5 mg SubQ once daily
One user reported wider stream and less inflammation within about five days and persistent improvement in later replies; other participants reported severe pain or no benefit, and no diagnosis or product assay was verified.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Positive accountImprovement within about 5 days
- Other accountNo benefit after 2 months
- Post-course claimsAbout 2–8 weeks of residual benefit; a separate report claims about 6 months
- Other follow-upsSymptoms returning, a failed rerun or prostate pain
Cycles people discuss
Community practice clusters around 10–20-day or roughly three-week courses, but inspected users also ran two months or discussed repeats months later. These calendars are convention and cost decisions, not validated human KEDP cycle biology.
Timing
Injection discussions use once-daily AM or PM routines, with some choosing morning for tracking; no controlled AM/PM advantage is established. Oral product guidance instead mentions food and 1–2 daily uses, with uncertain identity and absorption.
Stacks
Testagen, Libidon, Vesugen, herbals, tadalafil and lifestyle changes appear throughout prostate discussions. These products have different identities and make urinary, pain and sexual outcomes difficult to attribute to Prostamax alone.
Watch for
Diagnostic delay risk: Self-experimenting for urinary hesitancy, nocturia, pelvic pain, or hematuria can postpone workup for infection, obstruction, stones, or malignancy—community safety talk stresses clinician evaluation first.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A human parent-plasma half-life for synthetic Prostamax KEDP is not established by the reviewed evidence.
The primary compound-specific prostate paper tested 20 μg/kg IM for 15 days in rats after a surgical aseptic-inflammation model; it did not report a human PK clock.
This bounded review cannot prove no PK study exists. Extract products, in-vitro chromatin findings, once-daily conventions and claimed symptom persistence cannot substitute for exact-product human plasma measurements.
- Borovskaya et al. — Experimental studying of Prostamax in chronic aseptic prostatitis (opens in a new tab)Methods pages 1–2: Wistar rats received a silk-thread surgical ventral-prostate injury; Prostamax and Samprost were administered 20 μg/kg IM for 15 days beginning day 30, with morphologic endpoints at day 45.Surgically induced aseptic rat model, small morphologic study from the originating research line, not infection, spontaneous human BPH, a human efficacy trial or pharmacokinetic study.
Felt duration people report
A 5 mg/day user reported improvement within about five days; a different 1 mg/day user reported no benefit after two months. Other short-course and persistence reports conflict with symptom return and a failed rerun.
The morning 750 mcg/day account was confounded by mouth taping and reduced overnight water. A separate commenter reported improvement with Prostamax plus tadalafil followed by renewed trickling after a three-week course; that comment did not state an amount. A 5 mg/day user reported benefit, while distinct participants reported severe prostate pain or a failed rerun.
Anonymous uncontrolled reports, uncertain diagnoses, unverified product identity, dose and route disagreement, distinct authors and major lifestyle or medication confounding prevent a reliable felt-duration range.
- Reddit r/Peptides — Peptide Prostamax (opens in a new tab)Opening account and same-author replies: 750 mcg each morning for three weeks from a 20 mg vial; steadier/stronger stream and nocturia from four trips to one; mouth taping and less overnight water explicitly acknowledged as confounders.No confirmed diagnosis, symptom scale, PSA, product assay or control; lifestyle changed concurrently, and the thread also contains sourcing and preparation discussion not reproduced here.
- Reddit r/PeptideForum — Any experiences with Prostamax? (opens in a new tab)Visible replies: one user with self-reported BPH used injectable Prostamax 1 mg daily for two months and reported zero benefit, then reported no effect from Libidon; a different user claimed continued benefit after 5 mg twice daily for 20 days.Anonymous, unverified products and diagnoses; different authors must not be merged, the higher-dose claimant gave no detailed outcome or objective measurements, and Libidon is a different material.
- Reddit r/Peptides — Peptide for enlarged prostate? (opens in a new tab)Visible comments include deleted-author 750 mcg/day three-week courses, ECore's separate Prostamax-plus-tadalafil improvement followed by renewed trickling after three weeks without an amount, a deleted reply claiming roughly six-month persistence, and a separate 1,000 mcg/day day-three report without an established benefit. Deleted accounts cannot be securely joined to named authors.Deleted-account chronology and separate authors complicate attribution; products, diagnoses and routes were unverified, tadalafil and other changes confound outcomes, and follow-up is sparse.
- Reddit r/Prostatitis — Longterm BPH treated with Prostamax peptides (opens in a new tab)Opening and follow-ups: hanklazard reported 5 mg/day SubQ, improvement within about five days and continued benefit; distinct users reported severe prostate pain or no effect at 1 mg/day. Fast_Beat_3832 later called a rerun a bust and subsequently reported a PSA rise during use, a fall from about 15 to 13, and plans to retest after roughly six weeks off; timing and causality were unverified.Multiple distinct anonymous authors, unverified products and diagnoses, no baseline workup or controlled comparator; the PSA report cannot establish causality and is a reason not to delay clinical evaluation.
What people say
- Urinary flow / nocturia anecdotes: Sparse forum and blog posts claim easier stream, less night waking, or milder pelvic pressure after a short course—uncontrolled, often with herbals/PDE5/lifestyle confounds. anecdote
- Libido / ED halo: Occasional self-reports of better sexual comfort or drive; frequently co-used with tadalafil, Testagen, or extract products, so attribution is unreliable. anecdoteforum
- Stack halo: Inside multi-ingredient prostate or ‘men’s bioregulator’ stacks, credit is routinely assigned to Prostamax without isolation. forum
- What is not shown for synthetic KEDP: No published controlled human trial establishing reduced prostate volume, IPSS change, PSA normalization, prostatitis cure, fertility improvement, or cancer risk modification from research-chem Prostamax alone. trialforum
- Chronic prostatitis (animal): Borovskaya et al. (2013) gave Prostamax ~20 μg/kg IM for 15 days in a rat chronic aseptic prostatitis model and reported less swelling, vessel hyperemia, and lymphoid infiltration vs controls; authors also claimed restraint of sclerotic and atrophic remodeling vs some comparators (Samprost, Prostamol Uno). animal
- Organotypic / tissue culture: Russian organotypic prostate culture work (e.g. PMID 17152728 lineage) reports tissue-specific reparative/maintenance signals and reduced inflammatory remodeling talk in young and old rat tissues. labanimal
- BPH-style animal model: Experimental BPH-model writeups claim tetrapeptide Lys-Glu-Asp-Pro limited the sulpiride/androgen-driven rise in lateral-lobe mass, volume, and weight coefficient, with some comparisons vs Serenoa repens extract. animal
- Chromatin / cellular aging (in vitro): PMID 23221144—KEDP on cultured lymphocytes from elderly donors (75–86 y) reported deheterochromatinization (chromatin decondensation), more sister chromatid exchanges (~12/cell vs ~6 untreated in that report), more active nucleolar organizer regions, and reduced large pericentromeric heterochromatin segments. lab
- Lymphocyte heterochromatin (in situ): PMID 15612551 and related biophysical notes describe Prostamax effects on heterochromatin organization / thermal denaturation profiles in human lymphocytes—again molecular, not a prostate endpoint. lab
- Mating / sexual activity (animal): Same chronic-prostatitis animal line sometimes notes improved mating activity in treated models—preclinical only. animal
- Extract clinical halo (not synthetic): Prostatilen extract reports (e.g. PMID 2058122 prostatitis + sexual dysfunction; PMID 36318852 Prostatilen AC / zinc sperm-parameter work) drive much of the online ‘prostate peptide works’ reputation—those materials are not synthetic KEDP. trial
Doses people talk about
- Dominant research-chem short course: ~1–2 mg once daily (SC or IM) for ~10–20 consecutive days is the most-cited community pattern, following Russian bioregulator ‘course’ convention rather than continuous maintenance. forum
- Self-report example: One r/Peptides-style log described ~750 mcg morning SC for ~3 weeks from a 20 mg vial (roughly one vial per course at that rate). anecdote
- Alternative short inject charts: Blog/protocol tables sometimes list ~300–500 mcg SC daily for ~3–4 weeks, or ~1000 mcg Monday–Friday for ~2+ weeks. forum
- Outlier high-mg claims: A few web pages claim ~10–20 mg per day; that is inconsistent with typical 20 mg vial math and most forum practice—flag as unreliable/outlier, not consensus. forum
- Animal anchor (not human conversion): Chronic aseptic prostatitis rat work used ~20 μg/kg IM daily for 15 days (Prostamax vs Samprost comparators). Vendor ‘µg/kg human research’ tables (e.g. 5–20 / 20–100 / 100–500 µg/kg bands) are extrapolations, not clinical protocols. animalforum
- Oral / capsule products: Marketed bioregulator-style capsules or oral Khavinson-line products appear in catalogs (often ~1–2× daily for multi-week blocks); true free KEDP content, absorption, and identity vs multi-fraction Cytomax products are poorly verified. Oral peptide bioavailability is generally discussed as low without special formulation. forum
- Vial size: 20 mg lyophilized research vials dominate gray-market listings. forum
- Course math examples (community only): At 1 mg/day × 20 days ≈ one 20 mg vial per course; at 2 mg/day × 10 days ≈ one vial; at 200 µg/day × 10 days a 20 mg vial covers many courses if purity is real. forum
- Mid microgram–low mg band: Educational peptide-dosage pages commonly list ~500 mcg–1 mg once daily SC; some start ~500 mcg and step toward ~1 mg. forum
- Long titration ladders (educational sites, weak provenance): Multi-week charts step ~500 → 1000 → 2000 → ~3000 mcg once daily over ~8–12 (sometimes 16) weeks. These lack primary KEDP human dose-finding and conflict with classic 10–20 day bioregulator culture—treat as invention-heavy vendor content. forum
- Uncertainty stack: No purity/COA → labeled mg may not equal KEDP delivered; mcg vs mg unit errors are common; herbal ‘Prostamax’ bottles are not peptide mg. forum
- Framing: All figures below are discussion / vendor-chart / self-report ranges only—not validated human dose-finding, not prescriptions, not advice. Synthetic KEDP has no established clinical dose. forumtrial
How it may feel
- Days 4–10 (legacy mid-course window): Sparse earlier anecdotes place subtle urinary comfort or less pelvic awareness here, with many reporting nothing; these reports are placebo- and co-variable-prone. Separately, one inspected 5 mg/day SubQ user described improvement within about five days, while a 1 mg/day injectable user reported zero benefit after two months; neither establishes response probability. anecdoteforum
- End of 10–20 day course: Common checkpoint—quieter symptoms, ‘maybe better flow,’ or ‘nothing much.’ This is when most short-course users decide whether a re-run is worth it. forum
- Weeks 2–4 overall: For people on longer vendor charts (3–6+ weeks), community talk still frames change as gradual/subtle rather than sharp week-by-week steps. forum
- Weeks 2–8 after stopping (legacy anecdotal window): Older residual-benefit reports say symptoms stay quieter for weeks after the peptide is gone, while others say any edge fades without a repeat course; neither pattern is trial-verified for KEDP. Separately, one commenter reported improvement with Prostamax plus tadalafil and renewed trickling after three weeks, without stating an amount; a deleted reply claimed roughly six months, and another named user later called a repeat run a bust. These are different accounts. anecdoteforum
- Months 3–6: Discussion shifts from continuous daily use to 1–3 (sometimes up to ~4) short courses per year or restarts on seasonal flare. forum
- If nothing changes: Experienced community responses often redirect to urology workup (infection, obstruction, cancer, meds), sleep/alcohol/irritants, and product-identity/purity questions—not endless dose chasing. forum
- Days 1–3: Community logs usually report little to no systemic ‘feel’; injectors mainly notice site pinch/redness if anything. Gene-expression framing predicts no acute drug-like kick. forumanecdote
- Honesty: There is no published human onset/peak curve for synthetic Prostamax; timelines are convention + anecdote, not PK/PD. trial
Cycles people discuss
- Classic short blocks: 10–20 consecutive days is the dominant bioregulator pattern community sources repeat. forum
- Three–six week courses: Some self-reports and blog protocols run ~3–4 weeks daily (or M–F), sometimes framed as ‘initial course’ then rest. forumanecdote
- Long 8–16 week charts: Vendor educational ladders exist; they are less aligned with Khavinson short-course tradition and have no KEDP clinical dose-finding behind them. forum
- Off / spacing: Re-runs commonly framed as every ~3–6 months (~2–4× yearly), or after a ~2–4 week rest; flare-based restarts also discussed. forum
- Maintenance talk: A minority of charts describe EOD microdosing or lighter ‘maintenance’ after a loading course—unstandardized. forum
- Continuous daily years-long use: Less common and generally treated as non-standard vs short, repeatable courses. forum
- Monitoring culture: Thoughtful threads pair any experiment with PSA/urology follow-up and symptom scores (e.g. IPSS-style tracking talk)—not a formal trial requirement for the peptide itself. forum
- Animal study length echo: 15-day continuous IM regimens appear in the chronic prostatitis rat work—often cited as cultural support for ~2-week blocks, not as human proof. animal
Timing
- Forum / vendor claim: Short, hours-scale plasma presence is assumed for an unmodified tetrapeptide → once-daily dosing during courses, not weekly depot logic. forum
- Why short courses if half-life is short: Bioregulator tradition + gene-expression / chromatin narrative (effect framed as lasting past blood exposure), not long plasma half-life. forum
- Downstream residual: Weeks of quieter urinary symptoms after the course ends are anecdotal residual-benefit talk, not measured secondary messengers or tissue levels. anecdote
- Injection timing: Once daily AM or PM; no controlled AM/PM comparison. Some prefer morning for habit tracking. forum
- Oral timing: Capsule product guidance often with food 1–2× daily when oral forms are discussed—identity and absorption uncertain. forum
- PK honesty: Modern human PK packages (half-life, clearance, absolute bioavailability, prostate tissue distribution) for synthetic research-chem Prostamax are sparse to absent in Western literature. trial
More on what it is
- Why searched: Men’s-health + longevity niche wants a ‘prostate-specific’ peer to Epitalon/Thymalin; volume far below BPC-157 / recovery peptides. forum
- Mechanism talk: Originators frame ultrashort peptides as gene-expression / chromatin modulators that enter cells and interact with DNA regulatory regions—largely in-vitro theory, often oversimplified as ‘turns on silenced prostate genes.’ trialforum
- Not the same as: Not Prostatilen or Vitaprost (animal prostate polypeptide extracts); not Libidon (oral Cytomax-style multi-fraction prostate peptide complex); not Samprost (another prostate preparation used as animal comparator); not finasteride, tamsulosin, or proven BPH/cancer drugs. trialforum
- Name collision: Some markets sell herbal ‘Prostamax’ capsules (saw palmetto / nettle / zinc style). That is a different product class from research-chem KEDP lyophilizate—do not mix dosing or outcomes. forum
- Research lens: Never transfer extract-product clinical results, rectal-suppository practice, or IM clinic schedules onto unlabeled gray-market synthetic KEDP without stating the product identity gap. forum
- What it is: Synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP; ~487.5 g/mol), a Khavinson-group short-peptide bioregulator designed from prostate-tissue peptide lineage. trial
- Evidence honesty: Direct synthetic-KEDP human prostate RCTs are essentially absent. Compound-specific anchors are in-vitro chromatin work and Russian animal prostatitis/BPH models; human prostate outcomes usually cited online belong to the tissue extract Prostatilen/Vitaprost, not synthetic Prostamax. trialanimallab
Stacks
- Khavinson multi-course: Epitalon (pineal/longevity), Thymalin or thymic peptides, sometimes Pinealon—sequential or overlapping short courses. forum
- Men’s bioregulator cluster: Testagen (testicular), Libidon (oral prostate Cytomax complex—different material), occasional Vesugen/Vesilute (vascular/bladder-adjacent talk). forum
- Prostate extract sequencing: Some protocols sequence or confuse Prostamax with Prostatilen/Vitaprost/Samprost—identity errors common. forum
- Herbals / OTC: Saw palmetto, pygeum, beta-sitosterol, nettle, zinc—attribution unreliable when co-used. forum
- PDE5 / urologic meds: Tadalafil and similar appear in self-reports of urinary/sexual improvement—major confounders. anecdoteforum
- Non-drug: Hydration, fewer bladder irritants (caffeine/alcohol), pelvic floor PT, sleep, weight management, clinician eval for infection/obstruction. forum
- No validated stack ratios: Unlike fixed ‘Wolverine’ blends, Prostamax stacks are calendar co-administration, not fixed mg:mg premixes. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Diagnostic delay risk: Self-experimenting for urinary hesitancy, nocturia, pelvic pain, or hematuria can postpone workup for infection, obstruction, stones, or malignancy—community safety talk stresses clinician evaluation first. forum
- PSA / cancer context: Peptide interest does not replace age-appropriate PSA, DRE, imaging, or biopsy decisions; no evidence synthetic KEDP treats or prevents prostate cancer. forumtrial
- Source quality: Gray-market mislabeling, underfill, contamination, and endotoxin risks apply; COA claims vary and are not universal proof. forum
- Extract vs synthetic: Copying Prostatilen/Vitaprost doses, courses, or outcome claims onto KEDP overstates evidence and can produce wrong expectations. forumtrial
- Herbal name collision: Plant-based ‘Prostamax’ supplements (saw palmetto/nettle/zinc style) share a brand string but are not KEDP—wrong mechanism and wrong safety profile assumptions. forum
- Drug interaction data: No solid interaction packages with alpha-blockers, 5-ARIs, antibiotics, PDE5 inhibitors, anticoagulants, or hormone therapies. forum
- Immune / chromatin theoretical caution: In-vitro chromatin decondensation and lymphocyte effects are mechanism findings, not proof of safe long-term immune modulation in vivo. labforum
- Long-term / repeated courses: Preclinical anti-inflammatory signals ≠ proven multi-year safety for yearly re-runs in humans. animalforum
- Sterility / multi-use vials: Poor technique risks local infection; discard timelines are community convention, not stability-proven shelf-life studies for every vendor. forum
- Sparse AE tables: Controlled human adverse-event datasets for synthetic research-chem Prostamax are essentially absent; tolerability is unknown in a regulatory sense. trial
- Not risk-free framing: Emerging bioregulator + research-only labeling means absence of reported disasters is not evidence of safety. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.